Highest-materiality recent filing
Insmed reports positive 12-month OLE data for TPIP in PAH; sustained improvement across endpoints
6MWD improved +55.7m (TPIP continued) and +54.1m (placebo crossed) from baseline at Month 12.
Shareholders elect Anderson and Desjardins as Class II directors at annual meeting
Anderson received 153.7M for vs. 32.1M withheld; Desjardins 164.4M for vs. 21.4M withheld.
Insmed Q1 revenue $306M, BRINSUPRI $207.9M (44% QoQ); reiterates FY guidance
Total Q1 2026 revenue $306.0M vs $92.8M YoY; BRINSUPRI contributed $207.9M (+44% vs Q4 2025).
Insmed's brensocatib fails Phase 2b HS study; program discontinued
Primary endpoint not met: AN count reduction 45.5% (10mg) and 40.3% (40mg) vs 57.1% placebo at Week 16.
Insmed Reports Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE in MAC Lung Disease
Primary endpoint met: change from baseline in Respiratory Symptom Score at Month 13 showed 17.77 vs 14.66 points (p=0.0299).
Insmed reports FY2025 revenue $606M (+67% YoY); guides BRINSUPRI to at least $1B in FY2026
Full-year 2025 total revenues $606.4M (+67% YoY); ARIKAYCE $433.8M (+19%), BRINSUPRI $172.7M since Aug launch.
Insmed reports BRINSUPRI 2025 revs $172.7M; ARIKAYCE $433.8M; guides 2026 pipeline milestones
BRINSUPRI total revenues ~$172.7M for 2025 (~$144.6M in Q4 alone); ~4,000 prescribers, ~9,000 new patients in Q4.
Insmed brensocatib fails Phase 2b CRSsNP; acquires INS1148 antibody
Phase 2b BiRCh study missed primary endpoint: placebo LS mean -2.44, brensocatib 10mg -2.21, 40mg -2.33.
European Commission approves BRINSUPRI as first treatment for NCFB in EU
EC approved BRINSUPRI (brensocatib 25 mg) for NCFB patients 12+ years with ≥2 exacerbations in prior 12 months.
ARIKAYCE global revenue $114.3M (+22% YoY); 2025 guidance raised to $420M-$430M.
Insmed receives FDA approval for BRINSUPRI (brensocatib), first treatment for NCFB
FDA approved BRINSUPRI 10 mg and 25 mg for non-CF bronchiectasis in adults and children ≥12 years.
Insmed Q2 net loss $321.7M ($1.70/sh); ARIKAYCE revenue $107.4M (+19% YoY)
ARIKAYCE global revenue $107.4M, up 19% vs Q2 2024; US revenue $68.7M (+7.7%).
Insmed prices $750M common stock offering at $96/share for brensocatib R&D and commercialization
Priced 7,812,500 shares at $96.00; net proceeds ~$716.3M after underwriting discounts.
Insmed TPIP Phase 2b in PAH meets primary endpoint with 35% PVR reduction (p<0.001)
Placebo-adjusted PVR reduction 35% (p<0.001); 6MWD improvement 35.5 m (p=0.003); NT-proBNP reduction 60% (p<0.001).
Insmed completes redemption of remaining $1.97M 0.75% convertible notes due 2028
Redeemed $1,965,204.69 principal amount at 100% plus accrued interest on June 6, 2025.
Insmed shareholders elect Lee and Lewis; approve say-on-pay, auditor, incentive plan amendment
Shareholders elected Leo Lee (128.8M for) and William H. Lewis (140.7M for) as Class I directors.
Insmed Q1 revenue up 23% to $92.8M; net loss widens to $1.42/sh; brensocatib PDUFA Aug 12
ARIKAYCE total revenue $92.8M (+23% YoY); FY2025 guidance reaffirmed $405-425M.
Insmed adjusts conversion rate on 0.75% convertible notes; up to 17.8M shares issuable
Conversion rate increased to 31.2861 shares per $1,000 principal under make-whole provisions due to redemption notice.
Insmed calls all $569.5M of 0.75% Convertible Notes due 2028 for redemption on June 6, 2025
Company redeems $569.5M aggregate principal of 0.75% Convertible Senior Notes due 2028 on June 6, 2025.
Insmed CCO J. Drayton Wise resigns effective immediately for medical reasons; stays as consultant
J. Drayton Wise resigned as Chief Commercial Officer effective April 16, 2025, for personal and medical reasons, unrelated to operations.
FDA will not hold AdComm for Insmed's brensocatib; PDUFA date Aug 12, 2025
FDA communicated in Day 74 letter no advisory committee meeting is currently planned.
Insmed reports Q4 ARIKAYCE revenue $104.4M; brensocatib NDA accepted with Priority Review
Full-year 2024 ARIKAYCE revenue $363.7M (+19% YoY); Q4 net loss $235.5M ($1.32/share).
FDA grants priority review to Insmed's brensocatib NDA for bronchiectasis; PDUFA Aug 12, 2025
FDA accepted NDA with Priority Review; target action date August 12, 2025 under PDUFA.
Insmed reports preliminary 2024 ARIKAYCE revenue of $363.7M, sets 2025 guidance of $405-425M
Preliminary 2024 ARIKAYCE global net sales of $363.7M, up 19% YoY; 2025 guidance $405-425M (11-17% growth)
Insmed terminates $500M equity distribution agreement with Leerink Partners
Insmed terminated its Sales Agreement with Leerink Partners LLC, effective November 18, 2024.
Insmed Q3 ARIKAYCE revenue $93.4M (+18% YoY); net loss $1.27/sh; adds $150M loan
ARIKAYCE global revenue $93.4M in Q3 2024, up 18% YoY; US $66.9M, Japan $21.0M, Europe/RoW $5.6M.
Insmed completes redemption of $198K principal of 1.75% Convertible Notes due 2025
Redemption completed August 9, 2024; remaining $198,000 principal redeemed for cash at 100% plus accrued interest.
Insmed Q2 2024 revenue $90.3M (+17% YoY); net loss $300.6M; guides FY $340-360M
ARIKAYCE global revenue $90.3M in Q2 2024, up 17% YoY; U.S. $63.8M, Japan $21.1M, Europe $5.4M.
Brensocatib 25 mg showed significantly less FEV1 decline vs placebo (38 mL vs -62 mL; p=0.0054) at Week 52.
Insmed calls all $225M convertible notes due 2025; holders can convert to stock at ~$39.16
All $225M of 1.75% Convertible Senior Notes due 2025 called for redemption on August 9, 2024.
Insmed-AstraZeneca negotiation for brensocatib in COPD/asthma expires without agreement
AstraZeneca exercised final option for brensocatib in COPD/asthma on March 8, 2024.
Webinar at 8:00 a.m. ET on June 4, 2024, live via investor relations website.
Insmed prices $650M stock offering of 12.6M shares; net ~$713.9M
Offering of 12,621,359 shares at $51.50/share; net proceeds to Insmed of ~$713.9M (incl. option exercise).
Insmed Announces Positive Topline Results from Phase 3 ASPEN Study of Brensocatib in Bronchiectasis
ASPEN Phase 3 met primary endpoint: brensocatib 10mg and 25mg reduced annualized pulmonary exacerbations by 21.1% (p=0.0019) and 19.4% (p=0.0046) vs placebo.
Insmed shareholders elect four Class III directors and approve 2019 Incentive Plan amendment
Elected David R. Brennan, Leo Lee, Carol A. Schafer, Melvin Sharoky as Class III directors until 2027.
Insmed Q1 ARIKAYCE revenue $75.5M (+16%); TPIP PH-ILD shows strong clinical worsening signal
ARIKAYCE Q1 revenue $75.5M, up 16% YoY; net loss $157.1M ($1.06/share) vs $159.8M ($1.17) prior year.
AstraZeneca exercises final option to develop brensocatib in COPD/asthma
AstraZeneca exercised second option under 2016 license to develop brensocatib in COPD or asthma beyond Phase 2b.
Insmed Q4 net loss $186M; ARIKAYCE FY rev $305M (+24%), beats guidance; ASPEN data on track Q2 2024
Total revenue $83.7M in Q4 2023 (+41% YoY); full-year 2023 revenue $305.2M (+24% YoY), exceeding guidance.
Insmed reports prelim 2023 ARIKAYCE sales of ~$305.2M; guides 2024 to $340-360M
ARIKAYCE 2023 global net sales ~$305.2M, exceeding upper end of guidance, 24% YoY growth.
Insmed Q3 ARIKAYCE revenue $79.1M (+17% YoY); net loss $158.9M; FY23 guidance reaffirmed
ARIKAYCE global sales $79.1M for Q3, highest quarter since launch; U.S. $59.2M, Japan $16.0M.
ARISE validated QOL-B respiratory domain as PRO tool; to be proposed as primary endpoint for ENCORE without modification.
Insmed Q2 ARIKAYCE rev $77.2M (+18%), raises FY guide $295-305M; net loss $244.8M
ARIKAYCE global revenue $77.2M, 18% YoY growth, highest quarterly sales since launch.
Insmed sets annual say-on-pay votes after 99.85% shareholder approval
Shareholders voted 99.85% in favor of annual say-on-pay frequency at May 11, 2023 annual meeting.
Insmed shareholders approve incentive plan, elect directors, adopt universal proxy bylaws
Shareholders approved Amended and Restated 2019 Incentive Plan with 101.6M for, 11.0M against.
Insmed unveils four new research platforms; targets 6 INDs by 2025; DMD gene therapy trial in 2023
Gene therapy with targeted AAV delivery; DMD clinical trial to start 2023, muscle biopsy data expected H1 2024.
Insmed Q1 revenue up 23% to $65.2M; net loss widens to $159.8M; pipeline on track
ARIKAYCE global revenue $65.2M, up 23% YoY; U.S. net sales $49.1M, Japan $13.2M.
Insmed reports Q4 2022 ARIKAYCE revenue $59.3M, full year $245.4M; net loss $1.21 per share
ARIKAYCE global revenue grew 30% in 2022 to $245.4M; Q4 revenue $59.3M, impacted by $7.5M French pricing adjustment.
Insmed updates pipeline: ARIKAYCE 2023 rev guidance $285-300M; brensocatib CF data positive
ARIYACE global revenue 2022 up ~30% YoY; 2023 guidance $285-300M.
Insmed Q3 revenue $67.7M (+45% YoY); net loss $1.09/share; secures $775M financing
ARIKAYCE total revenue of $67.7M: $49.5M U.S., $14.5M Japan, $3.7M Europe/RoW.
Insmed raises $775M via term loan, royalty deal, and equity offering to fund pipeline
$350M senior secured term loan from Pharmakon Advisors, maturing Oct 2027, at SOFR+7.75% (floor 2.5%).
On April 16, 2025, J. Drayton Wise notified Insmed Incorporated (the “Company”) of his decision to resign from his position as the Company’s Chief Commercial Officer for personal and medical reasons, effective immediately.
On February 18, 2025, Alfred Altomari notified the board of directors (the “Board”) of the Company that he will not stand for re-election to the Board upon the expiration of his current term as a Class I director, which occurs at the Company’s 2025 Annual Meeting of Shareholders (the “Annual Meeting”).
On May 23, 2022, Insmed Incorporated (the “Company”) announced that Mr. Drayton Wise has been appointed as Chief Commercial Officer of the Company, effective immediately.
On February 15, 2022, Steinar J. Engelsen, M.D. notified the board of directors (the “Board”) of the Company that he will not stand for re-election to the Board upon the expiration of his current term as a Class I director, which occurs at the Company’s 2022 Annual Meeting of Shareholders (the “Annual Meeting”).
Max materiality 1.00 · Median 0.75 · Most common event other_material